Market Place
Sourcing Support
Mirum Pharma Presents Rare Liver Disease Data at EASL 2026
30 May 2026 //
PRESS RELEASE
Mirum Pharma to Present Rare Liver Disease Data at EASL 2026
21 May 2026 //
BUSINESSWIRE
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Rule
14 May 2026 //
BUSINESSWIRE
Mirum Pharmaceuticals Proposes Convertible Senior Notes Offering
12 May 2026 //
BUSINESSWIRE
Mirum Pharmaceuticals Prices $600M Convertible Notes Offering
12 May 2026 //
BUSINESSWIRE
Mirum Pharma Reveals Q1 2026 Financials And Business Update
06 May 2026 //
FIRSTWORD PHARMA
Mirum Pharma Reports VISTAS Primary Endpoint Met for Volixibat
04 May 2026 //
BUSINESSWIRE
Mirum`s rare liver Disease Drug Meets Main Goal in Mid-Stage
04 May 2026 //
REUTERS
Mirum Pharma to Share Topline VISTAS Volixibat Results on May 4
03 May 2026 //
BUSINESSWIRE
Mirum Pharma to Report Q1 2026 Results and Host Call May 6
29 Apr 2026 //
BUSINESSWIRE
Mirum`s Brelovitug Meets Primary Endpoint in Hep Delta Trial
27 Apr 2026 //
FIRSTWORD PHARMA
Mirum Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
13 Apr 2026 //
BUSINESSWIRE
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq
12 Mar 2026 //
BUSSINESSWIRE
Mirum Pharmaceuticals Provides AZURE Clinical Program Update
05 Mar 2026 //
BUSINESSWIRE
Mirum Pharma Reveals 2025 Q4 Results And Business Update
25 Feb 2026 //
BUSINESSWIRE
Mirum Pharma To Join Investor Conferences
23 Feb 2026 //
BUSINESSWIRE
Mirum Pharma To Unveil Q4 2025 Financials, Hold Conference Call
18 Feb 2026 //
BUSINESSWIRE
Mirum Pharma Announces Health Canada Authorization of Livmarli
05 Feb 2026 //
BUSINESSWIRE
Mirum Pharma Acquires Bluejay to Boost Rare Disease Leadership
26 Jan 2026 //
BUSINESSWIRE
Mirum Pharma Posts Strong 2025 Growth Results
12 Jan 2026 //
BUSINESSWIRE
Mirum Pharma Discloses Inducement Grants Per Nasdaq LR 5635(C)(4)
12 Jan 2026 //
BUSINESSWIRE
Enthorin Starts Phase 2 Trial Of MRM-3379 For Fragile X Syndrome
09 Jan 2026 //
BUSINESSWIRE
Mirum Pharma To Present At 44th J.P. Morgan Healthcare Conference
07 Jan 2026 //
BUSINESSWIRE
Mirum Pharma Secures More Private Funding From TCGX
19 Dec 2025 //
PHARMIWEB
Mirum Pharma Issues Inducement Grants Under Nasdaq Rule
10 Dec 2025 //
BUSINESSWIRE
Mirum Pharma Enters into Definitive Agreement to Acquire Bluejay
08 Dec 2025 //
PHARMIWEB
Mirum Pharma Enrolls First Patient In BLOOM Ph2 Study
01 Dec 2025 //
BUSINESSWIRE
Mirum Pharma To Join Investor Conferences
25 Nov 2025 //
BUSINESSWIRE
Mirum Pharma Discloses Inducement Grants Per Nasdaq LR 5635(C)(4)
10 Nov 2025 //
BUSINESS WIRE
Mirum Highlights LIVMARLI And Volixibat Data At Liver Meeting
07 Nov 2025 //
BUSINESSWIRE
Mirum Pharma Reveals Q3 2025 Financials & Business Update
04 Nov 2025 //
BUSINESSWIRE
Mirum Pharma To Join Investor Conferences
03 Nov 2025 //
BUSINESSWIRE
Mirum Pharma To Unveil Q3 2025 Financials, Host Call On Nov 4
28 Oct 2025 //
BUSINESSWIRE
Mirum Pharma Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
10 Oct 2025 //
BUSINESSWIRE
Mirum Pharma Gives Inducement Grants Under Nasdaq Rule 5635(c)(4)
10 Sep 2025 //
BUSINESSWIRE
Mirum Pharma Completes Phase 2b VISTAS Study Enrollment
08 Sep 2025 //
BUSINESSWIRE
Mirum Pharmaceuticals to Present at Investor Conferences
27 Aug 2025 //
BUSINESSWIRE
Mirum Pharmaceuticals Q2 2025 Financial Results & Business Update
06 Aug 2025 //
BUSINESSWIRE
Mirum Pharma Q2 2025 Financial Results Conference on August 6
30 Jul 2025 //
BUSINESSWIRE
Mirum Pharmaceuticals Issues Inducement Grants per Nasdaq Rule
10 Jul 2025 //
BUSINESSWIRE
Mirum Pharma Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
10 Jun 2025 //
BUSINESSWIRE
Mirum Pharmaceuticals Names Doug Sheehy as Chief Legal Officer
19 May 2025 //
BUSINESSWIRE
Mirum Pharmaceuticals to Join Investor Conferences
14 May 2025 //
BUSINESSWIRE
Volixibat Data from Mirum`s VANTAGE PBC Study Showcased at EASL
09 May 2025 //
BUSINESSWIRE
Mirum Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
09 May 2025 //
BUSINESSWIRE
Mirum Pharmaceuticals Reports Q1 2025 Results and Update
07 May 2025 //
BUSINESSWIRE
Mirum Pharmaceuticals to Announce Q1 2025 Results on May 7
30 Apr 2025 //
BUSINESSWIRE
Mirum Pharmaceuticals to Present Data at Medical Congresses
28 Apr 2025 //
BUSINESSWIRE
Mirum`s Livmarli Now FDA Approved in Tablet Formulation
14 Apr 2025 //
BUSINESSWIRE
Mirum Pharma Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
10 Apr 2025 //
BUSINESSWIRE
Livmarli Now Approved in Japan for ALGS and PFIC
27 Mar 2025 //
BUSINESSWIRE
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq List
10 Mar 2025 //
BUSINESSWIRE
Mirum Reports Q4, Full-Year 2024 Results & Business Update
26 Feb 2025 //
BUSINESSWIRE
US FDA approves Mirum Pharma`s genetic disorder drug
22 Feb 2025 //
REUTERS
FDA Approves First Treatment For Cerebrotendinous Xanthomatosis
21 Feb 2025 //
PR NEWSWIRE
Mirum Pharma Sets Feb 26 For Q4, Full-Year 2024 Results Call
19 Feb 2025 //
BUSINESSWIRE
Mirum Pharma Reports Inducement Grants Under NasdaqLR 5635(c)(4)
10 Feb 2025 //
BUSINESSWIRE
Mirum Pharma Reports 2024 Sales, Cash Balance, and Updates
13 Jan 2025 //
BUSINESSWIRE
Mirum Pharma to Present at the 43rd Annual J.P. Morgan Conference
06 Jan 2025 //
BUSINESSWIRE
Mirum Pharma Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
11 Dec 2024 //
BUSINESSWIRE
